Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
niacinamide + zinc sulfate + copper is an oral combination therapy primarily utilized for the management of inflammatory dermatological conditions, including acne vulgaris and rosacea. Niacinamide, a form of vitamin B3, exerts potent anti-inflammatory effects by inhibiting poly(ADP-ribose) polymerase-1 (PARP-1) and reducing the production of pro-inflammatory cytokines such as IL-8 and TNF-alpha. Zinc sulfate serves as an antimicrobial and anti-inflammatory agent, helping to reduce sebum production and inhibit the growth of *Cutibacterium acnes* (formerly *Propionibacterium acnes*). Copper is included in the formulation to mitigate the risk of zinc-induced copper deficiency, a potential side effect of long-term zinc supplementation. This combination is frequently classified as a medical food or prescription dietary supplement in the United States.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on niacinamide + zinc sulfate + copper.